Enochian Biosciences, Inc. (ENOB)
| Market Cap | 382.37M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -13.46M |
| Shares Out | 51.95M |
| EPS (ttm) | -0.29 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 203,141 |
| Open | 7.26 |
| Previous Close | 6.98 |
| Day's Range | 7.07 - 7.60 |
| 52-Week Range | 2.60 - 12.99 |
| Beta | 0.37 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | n/a |
About ENOB
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-HB-01, a coopting Hepatitis B polymerase; ENOB-DC-01, an off-the-shelf DC vaccine pulsed with MCV lysate; ENOB-DC-11 inno...
Financial Performance
Financial StatementsNews
Distinguished Scientific and Public Health Leaders to Join Enochian BioSciences' Scientific Advisory Board for Potent...
LOS ANGELES, Aug. 30, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene-modified cellular and immune therapies for infectious diseases and cancer, announced the a...
Distinguished Scientific and Clinical Leader to Join Enochian BioSciences' Hepatitis B Cure Scientific Advisory Board
LOS ANGELES, Aug. 23, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene modified cellular and immune therapies for infectious diseases and cancer, announced that ...
Enochian BioSciences Names The Hon. Dr. Mark Dybul as Chief Executive Officer
Dr. Dybul's Deep and Prestigious Scientific Research Expertise Helps to Affirm Enochian BioSciences' Scientific Approach Dr. Dybul's Deep and Prestigious Scientific Research Expertise Helps to Affirm En...
Enochian Stock Is Trading Higher On FDA Acceptance of Pre-IND Request For Hepatitis B Program
Enochian BioSciences Inc (NASDAQ: ENOB) has announced that the FDA has accepted a Pre-IND (Investigational New Drug) request for a potential cure of hepatitis B virus (HBV) infection. Written comments a...
Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential Cure for Hepatitis B Virus Infection
LOS ANGELES, July 12, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today anno...
Enochian BioSciences Announces Scientific Presentation of Elimination of HBV in Mice with No Evident Toxicity
LOS ANGELES, June 30, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today anno...
Why Enochian BioSciences Was a Winner on Monday
The company scores an exclusive license for new potential coronavirus treatment technology.
Why Enochian Biosciences, Raven Industries And GE Share Are Trading Higher Today
Enochian Biosciences Inc (NASDAQ:ENOB) shares are trading higher by 11.7% at $6.48 Monday morning after the company announced it acquired an exclusive license for an innovative technology to potentially...
Enochian BioSciences Stock Is Trading Higher After In-Licensing COVID-19, Influenza Inhaled Treatment Technology
Enochian BioSciences Inc (NASDAQ: ENOB) has acquired an exclusive license for a technology to potentially treat and prevent all variants of coronavirus, including the cause of COVID-19, as well as influ...
Enochian BioSciences Announces Acquisition of Exclusive License for Potential Pan-Coronavirus and Pan-Influenza Inhal...
Request for Pre-Investigator New Drug Meeting to Be Submitted to FDA in Near Term Request for Pre-Investigator New Drug Meeting to Be Submitted to FDA in Near Term
Pioneering Research Institute In Los Angeles Moves One Step Closer To Finding A Cure For HIV
LOS ANGELES, June 15, 2021 /PRNewswire/ -- (NASDAQ: ENOB) – A promising cure for HIV is moving one step closer to FDA approval. The novel approach to treating HIV in humans using cell therapy, developed...
Here's Why Enochian BioSciences Stock Skyrocketed Today
The biotech's experimental treatment for HIV could be a game changer.
Enochian BioSciences Announces $29 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
LOS ANGELES, June 14, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today ann...
ENOB Stock: The HIV Treatment News That Has Enochain Biosciences Skyrocketing Today
Shares of ENOB stock are taking off on Monday after Enochain Biosciences received FDA acceptance for its vital HIV treatment. The post ENOB Stock: The HIV Treatment News That Has Enochain Biosciences Sk...
Hot Penny Stocks For Your Weekly Watchlist in June
Making a penny stocks watchlist this week? Check these 3 small-caps out The post Hot Penny Stocks For Your Weekly Watchlist in June appeared first on Penny Stocks to Buy, Picks, News and Information | P...
Why Is Enochian BioSciences (ENOB) Stock Surging Today?
The FDA has accepted Enochian BioSciences Inc's (NASDAQ: ENOB) pre-IND (Investigational New Drug) request for a potential functional cure or treatment of HIV. Written comments are expected this Fall.
Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential HIV Cure
LOS ANGELES, June 14, 2021 (GLOBE NEWSWIRE) -- Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that the FD...
Enochian BioSciences announces Scientific Presentation of a Person with HIV Exhibiting Controlled Blood Levels of Vir...
LOS ANGELES, May 12, 2021 (GLOBE NEWSWIRE) -- Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced the release ...
A Promising Approach To HIV Cell Therapy, With Exciting Preliminary Results, Was Presented Recently At The Leading Co...
LOS ANGELES, May 12, 2021 /PRNewswire/ -- (NASDAQ: ENOB) – A novel approach to HIV cell therapy developed by Dr. Serhat Gumrukçu (Dr. Serhat), Director of the Seraph Research Institute (SRI), and his t...
Seraph Research Institute and Enochian BioSciences Publish a Case Report of Complete Remission of Recurrent Glioblast...
LOS ANGELES, March 24, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Seraph Research Institute (SRI) and Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infec...
Enochian BioSciences to Present to Investors at the H.C. Wainwright Global Life Sciences Conference
LOS ANGELES, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will be m...
Enochian BioSciences to Present to Investors at 22nd Annual H.C. Wainwright Global Investment Conference
LOS ANGELES, Sept. 10, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences , a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today annou...
Here's Why Small-Cap Biopharma Enochian Is Surging Higher
Shares of Enochian Biosciences Inc (NASDAQ: ENOB) were trading more than 75% higher Monday in reaction to the company's announcement regarding a positive FDA meeting regarding its HIV candidate.
Enochian Bio’s HIV Treatment Is on Its Way With the FDA
Enochian BioSciences Inc. (NASDAQ: ENOB) shares more than doubled to start out the week after the company received a critical update from the U.S.